

Hong Kong Exchange s and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibilities for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CONCORD HEALTHCARE GROUP CO., LTD.

美中嘉和醫學技術發展集團股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2453)

VOLUNTARY ANNOUNCEMENT IMPORTANT COOPERATION AGREEMENT

This announcement is made by the board of directors (the “**Board**”) of Concord Healthcare Group Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The Board is pleased to announce that the Group entered into an important cooperation agreement with the Ministry of Health of the Republic of Uzbekistan (the “**Ministry of Health**”) on 29 July 2026 for the construction and operation of a Gamma Knife stereotactic radiosurgery centre at the Tashkent National Medical Centre (the National Medical Centre of the Ministry of Health of the Republic of Uzbekistan, located in Tashkent, the Republic of Uzbekistan).

Leveraging its strengths in on-site medical premises, national medical insurance system and local healthcare resources, the Ministry of Health has collaborated with the Group under a Public-Private Partnership (“**PPP**”) framework. Drawing on the Group’s long-standing and proven expertise in oncological radiotherapy, Gamma Knife centre operation, high-end medical equipment administration and clinical services, the Company will make full investment and take charge of the operation of the Tashkent Gamma Knife centre for a cooperation term of 15 years, with both parties sharing the project proceeds. The cooperation facilitates the Group’s strategic deployment of high-end oncological radiotherapy business across Central Asia and fosters business synergy with Guangzhou Taihe Cancer Hospital (the “**Guangzhou Hospital**”) under the Group.

The Board is of the view that the Agreement was concluded after arm’s length negotiations between the Group and the Ministry of Health on normal commercial terms, and the cooperation is in the overall interests of the Group and its shareholders as a whole.

REASONS FOR AND BENEFITS OF ENTERING INTO THE COOPERATION AGREEMENT

This cooperation constitutes a vital milestone in the Group’s international expansion into the Central Asian market. The Group realises asset-light technology export by virtue of its well-honed capabilities in oncological radiotherapy, Gamma Knife operation and management as well as artificial intelligence technologies, forming a replicable model for overseas medical cooperation. Upon project commencement, the Gamma Knife business will form effective complementarity with the proton therapy services provided by the Guangzhou Hospital, enabling the establishment of a

cross-border multidisciplinary consultation and patient referral system to continuously elevate the Group's brand influence. Meanwhile, the project will generate a steady new source of overseas revenue, optimise the geographical composition of income, enrich the industrial chain of high-end oncological radiotherapy services and strengthen the overall operational capacity of the Group. Building on the success of this cooperation, both parties will further deepen their cooperation, and will further strengthen cooperation in areas such as the joint establishment and operation of radiotherapy centres and diagnostic imaging centres, as well as AI applications.

INFORMATION OF THE PARTIES

The Company is a joint stock company with limited liability incorporated under the laws of the PRC, with its H Shares listed on the Stock Exchange on January 9, 2024. The Company is an oncology healthcare service provider in China serving both cancer patients through its self-owned medical institutions and third-party medical institutions through its medical equipment, software and related services.

Acting on behalf of the Republic of Uzbekistan, the Ministry of Health exercises its authority pursuant to the Law on Public-Private Partnership No. 537 dated 10 May 2019, the Regulation on Public-Private Partnership in the Healthcare Sector approved under Presidential Decree No. 4290 dated 16 April 2019, and the Regulation on the Ministry of Health of the Republic of Uzbekistan approved under Cabinet Resolution No. 714 dated 12 September 2017.

To the best of the Company's directors' knowledge, information and belief, Ministry of Health and its ultimate beneficial owners are third parties independent of the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")).

LISTING RULES IMPLICATION

As at the date of this announcement, entering into the Agreement and the transactions contemplated thereunder do not constitute notifiable transactions or connected transactions under Listing Rules.

The Company will keep the shareholders and potential investors of the Company informed of any further update in relation to the above by further announcement(s) made by the Company as and when appropriate in compliance with the Listing Rules.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Concord Healthcare Group Co., Ltd.
YANG Jianyu
Chairman of the Board and Executive Director

Beijing, the PRC, July 29, 2026

As at the date of this announcement, the Board comprises (i) Dr. YANG Jianyu, and Mr. JIANG Wei as executive Directors; (ii) Mr. WANG Lei, Mr. SONG Qingbao and Mr. SHI Botao as non-executive Directors; (iii) Ms. LI Xuemei, Mr. SUN Yansheng and Mr. NG Kwok Yin as independent non-executive Directors; and (iv) Ms. JIANG Li as employee Director.